Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Clinical Trials

Volumn 10, Issue 3, 2013, Pages 422-429

  Hoering, Antje ^a   Mitchell, Alan ^a   Leblanc, Michael ^a   Crowley, John ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG TOXICITY; HUMAN; HYPOTHESIS; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; RECOMMENDED DRUG DOSE; SIMULATION; STUDY DESIGN; TITRIMETRY;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; CYTOSTATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84878231586     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513480961     Document Type: Article

References (15)

1. Hoering A, LeBlanc M, Crowley J. Seamless phase I/II trial design for assessing toxicity and efficacy for targeted agents. Clin Cancer Res. 2011 ; 17 (4). 640-46
2. Hoering A, LeBlanc M, Crowley J Handbook of Statistics in Clinical Oncology. 3 rd edn). Boca Raton, London, New York: CRC Press, 2012, pp. 97-106. Crowley J Hoering A, ed. Boca Raton, London, New York: CRC Press ; 2012: 97-106.
3. Storer BE Handbook of Statistics in Clinical Oncology. 3 rd edn). Boca Raton, London, New York: CRC Press, 2012, pp. 85-95. Crowley J Hoering A, ed. Boca Raton, London, New York: CRC Press ; 2012: 85-95.
4. Penel N, Isambert N, Leblond P, et al. 'Classical 3+3 design' versus 'accelerated titration designs': Analysis of 270 phase I trials investigating anti-cancer agents. Invest New Drugs. 2009 ; 27: 552-56
5. Ivy P, Siu L, Garrett-Mayer E. Approaches to phase I clinical trial design focused on safety, efficiency and selected patient populations: A report from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010 ; 16: 1726-36
6. O'Quigley J, Iasonos A Handbook of Statistics in Clinical Oncology. 3 rd edn). CRC Press, London, 2012, pp. 21-51. Crowley J Hoering A, ed. London: CRC Press ; 2012: 21-51.
7. Simon R, Freidlin B, Rubenstein L. Accelerated titration designs for phase I clinical trial in oncology. et al J Natl Cancer Inst. 1997 ; 89: 1138-47
8. Rogatko A, Schoeneck D, Jonas W. Translation of innovative designs into phase I trials. et al J Clin Oncol. 2007 ; 25: 4982-86
9. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004 ; 60: 684-93
10. Mandrekar S, Sargent D Handbook of Statistics in Clinical Oncology. 3 rd edn). Boca Raton, London, New York: CRC Press, 2012, 85-95. Crowley J Hoering A, ed. Boca Raton, London, New York: CRC Press ; 85-95.
11. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med. 2005 ; 24: 2171-81
12. YeeTW. The VGAMpackage for categorical data analysis. J Stat Softw2010; 32: 1-34, http://www.jstatsoft.org/v32/i10/
13. McCullagh P, Nelder JA Generalized Linear Models. 2 nd edn). London: Chapman & Hall, 1989. London: Chapman & Hall ; 1989 :
14. Dale JR. Global cross-ratio models for bivariate, discrete, ordered responses. Biometrics. 1986 ; 42: 909-17
15. Simon R, Wittes RE, Ellensberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985 ; 69: 1051-60